
Magenta Therapeutics MGTA
Annual report 2025
added 03-09-2026
Magenta Therapeutics P/CF Ratio 2011-2026 | MGTA
Annual P/CF Ratio Magenta Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -0.0979 | -0.0229 | -2.91 | -6.63 | -7.56 | -2.55 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.0229 | -7.56 | -3.29 |
P/CF Ratio of other stocks in the Biotechnology industry
| Issuer | P/CF Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-0.654 | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
-0.266 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
11.6 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.68 K | - | 2.54 % | $ 160 B | ||
|
Autolus Therapeutics plc
AUTL
|
-1.14 | $ 1.36 | -2.52 % | $ 362 M | ||
|
Biophytis SA
BPTS
|
-23.1 | - | -13.47 % | $ 169 M | ||
|
Midatech Pharma plc
MTP
|
-13.2 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.88 | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
-1.2 | - | -24.86 % | $ 820 K | ||
|
DBV Technologies S.A.
DBVT
|
-23.3 | $ 20.25 | -0.54 % | $ 2.83 B | ||
|
Dyadic International
DYAI
|
-5.52 | $ 0.87 | 0.59 % | $ 31.5 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-94.9 | $ 3.78 | 4.83 % | $ 9.09 B | ||
|
Advaxis
ADXS
|
-0.0633 | - | -9.65 % | $ 45.9 M | ||
|
Adverum Biotechnologies
ADVM
|
-0.826 | - | - | $ 86.2 M | ||
|
Aytu BioScience
AYTU
|
-8.14 | $ 2.6 | -2.26 % | $ 16.3 M | ||
|
Институт стволовых клеток человека
ISKJ
|
-89 | - | - | - | ||
|
Fate Therapeutics
FATE
|
-1.76 | $ 1.14 | -4.2 % | $ 135 M | ||
|
Forte Biosciences
FBRX
|
-6.59 | $ 26.44 | - | $ 342 M | ||
|
Aeterna Zentaris
AEZS
|
-4.82 | - | 5.93 % | $ 314 M | ||
|
Fennec Pharmaceuticals
FENC
|
-13.5 | $ 6.16 | -4.05 % | $ 176 M | ||
|
AgeX Therapeutics
AGE
|
-0.0018 | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-4.6 | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.64 | - | - | $ 26.5 M | ||
|
Amicus Therapeutics
FOLD
|
134 | $ 14.46 | 0.03 % | $ 4.46 B | ||
|
AIkido Pharma
AIKI
|
-1.17 | - | 1.93 % | $ 17.4 M | ||
|
Fulcrum Therapeutics
FULC
|
-0.00898 | $ 7.57 | -3.32 % | $ 480 K | ||
|
Aptose Biosciences
APTO
|
-0.0645 | - | -45.71 % | $ 1.2 M | ||
|
Galectin Therapeutics
GALT
|
-7.47 | $ 2.28 | -11.13 % | $ 146 M | ||
|
Gilead Sciences
GILD
|
18.3 | $ 138.34 | -1.28 % | $ 172 B | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-0.212 | $ 0.54 | 4.28 % | $ 503 K | ||
|
Akero Therapeutics
AKRO
|
-14.1 | - | - | $ 3.67 B | ||
|
Genmab A/S
GMAB
|
4.08 | $ 27.14 | -2.2 % | $ 17 B | ||
|
CureVac N.V.
CVAC
|
-4.82 | - | - | $ 867 M | ||
|
BioNTech SE
BNTX
|
70.7 | $ 88.2 | -3.37 % | $ 27.2 B | ||
|
Gossamer Bio
GOSS
|
-0.627 | $ 0.32 | -7.11 % | $ 73.1 M | ||
|
Coherus BioSciences
CHRS
|
-1.63 | $ 1.62 | -3.29 % | $ 190 M | ||
|
Grifols, S.A.
GRFS
|
14.1 | $ 7.98 | -3.04 % | $ 6.83 B | ||
|
Akari Therapeutics, Plc
AKTX
|
-765 | $ 3.5 | -1.13 % | $ 236 B | ||
|
Akouos
AKUS
|
-2.7 | - | 0.23 % | $ 488 M | ||
|
GT Biopharma
GTBP
|
-0.201 | $ 0.41 | -8.56 % | $ 2.26 M | ||
|
Allakos
ALLK
|
-0.976 | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
-2.48 | - | 3.16 % | $ 1.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
77.9 | $ 316.69 | -4.13 % | $ 41.5 B | ||
|
Halozyme Therapeutics
HALO
|
14.8 | $ 63.72 | 1.01 % | $ 7.64 B | ||
|
Alpine Immune Sciences
ALPN
|
-6.14 | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
-1.71 | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
-0.632 | - | 4.14 % | $ 49.1 M | ||
|
Harmony Biosciences Holdings
HRMY
|
4.62 | $ 27.53 | -0.67 % | $ 1.58 B | ||
|
Burford Capital Limited
BUR
|
11.6 | $ 4.53 | 1.0 % | $ 726 M | ||
|
Atreca
BCEL
|
-0.607 | - | -11.76 % | $ 5.79 M |